Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Abbott Laboratories

16 shared events · Importance 3 · Last updated Sep 24, 2026

Importance
3
Shared Events
16
Actions
2
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
95
Regulatory
United States — Food and Drug Administration: The FDA granted De Novo authorization to Abbott's device, establishing new regulatory standards for continuous ketone monitoring. This action expands the regulatory framework for diabetes technology.
Abbott Laboratories: Abbott is the developer and manufacturer of the Libre Duo 10 Day system, receiving FDA authorization for the world's first dual glucose-ketone sensor. This approval strengthens its diabetes care franchise and is expected to drive future revenue growth.
Aug 25, 2026 · 21 articles
89
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration granted 510(k) clearance for the Diazyme Lipoprotein(a) Molarity Assay, enabling its use in clinical laboratories.
Abbott Laboratories: Abbott Laboratories, Inc. received 510(k) clearance from the United States — Food and Drug Administration for its Lipoprotein(a) Molarity Assay, which is a significant step forward for the company in cardiovascular risk assessment.
Jun 18, 2026 · 6 articles
85
Regulatory
United States — Food and Drug Administration: The FDA approved SimpleScreen CRC, adding a new blood-based screening option for colorectal cancer.
Abbott Laboratories: Abbott will exclusively commercialize SimpleScreen CRC, expanding its colorectal cancer screening portfolio alongside Cologuard, and leveraging its existing infrastructure.
Jul 27, 2026 · 6 articles
67
Regulatory
United States — Food and Drug Administration: FDA inspectors found unsanitary conditions and Cronobacter sakazakii strains at the Sturgis plant, and the agency gained five-year oversight of the facility under a consent decree.
Abbott Laboratories: Abbott is the central party, paying about $385 million to settle False Claims Act allegations over contaminated infant formula without admitting fault. The resolution removes legal uncertainty but keeps reputational and regulatory risk tied to its nutrition business.
Sep 14, 2026 · 6 articles
60
Regulatory
United States — Food and Drug Administration: Its advisory panel endorsed the test, but the agency still must make the final approval decision and has flagged efficacy concerns.
Abbott Laboratories: Pursuing its own multi-cancer test, CancerGuard; a Grail approval would validate the field but also set a competitive bar and regulatory precedent.
Sep 23, 2026 · 18 articles
52
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration is currently reviewing Abbott's dual glucose-ketone system, and its clearance is necessary for commercialization in the United States.
Abbott Laboratories: Abbott is collaborating with Medtronic — Medtronic MiniMed to commercialize its dual glucose-ketone sensors, expanding its reach in diabetes technology and potentially increasing revenue from its medical device segment.
Jun 03, 2026 · 7 articles
45
Business
United States — Food and Drug Administration: The new facility will be built to USFDA standards, ensuring regulatory compliance for the US market, which is critical for the partnership's success.
Abbott Laboratories: Neuland gains dedicated sterile API manufacturing capacity through Gland Pharma, supporting its growing demand and enhancing its CDMO capabilities. The corporate guarantee of ₹40 crore reflects its commitment.
Aug 05, 2026 · 6 articles
45
Business
United States — Food and Drug Administration: The FDA, along with other agencies, issued a statement that there is no conclusive evidence that preterm formula causes NEC, which supports the companies' defense.
Abbott Laboratories: Abbott is the primary defendant, agreeing to pay $670 million to settle part of the NEC litigation. The settlement reduces legal uncertainty but does not resolve all claims, and the company continues to face thousands of lawsuits.
Aug 20, 2026 · 20 articles
40
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration>>> (FDA) is the regulatory body reviewing Alvogen's resubmitted applications for AVT05 and AVT06. Their decision will determine the market entry of these biosimilars in the United States>>>.
Abbott Laboratories: Abbott Laboratories>>> is partnered with Alvogen>>> for AVT03, a different biosimilar. While not directly involved in the current resubmissions, their partnership with Alvogen>>> indicates a broader strategy in the biosimilar market.
Jun 04, 2026 · 10 articles
38
Business
United States — Food and Drug Administration: Has approved twice-yearly lenacapavir for HIV prevention, while the once-yearly formulation covered by the new licence remains unapproved.
Abbott Laboratories: Signed the royalty-free non-exclusive voluntary licence for once-yearly lenacapavir, expanding its HIV prevention portfolio and public-health access franchise across 120 licensed countries.
Sep 17, 2026 · 6 articles
32
Business
United States — Food and Drug Administration: Carolina Liquid Chemistries Corporation is an FDA registered manufacturer, indicating its compliance with regulatory standards.
Abbott Laboratories: Abbott Laboratories acquired Carolina Liquid Chemistries Corporation, expanding its diagnostic capabilities and product offerings. This acquisition is expected to create synergies and benefit laboratories of all sizes.
Jun 01, 2026 · 7 articles
20
Business
United States — Food and Drug Administration: The company's US FDA approval is a key quality indicator that supports its credibility and market position, indirectly contributing to the IPO's success.
Abbott Laboratories: As a listed peer, Abbott Laboratories may see valuation comparisons and investor interest spillover.
Aug 19, 2026 · 20 articles
0
Regulatory
Apr 17, 2026 · 6 articles
0
Domestic
May 04, 2026 · 58 articles
0
Domestic
May 08, 2026 · 114 articles
0
Regulatory
May 01, 2026 · 78 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Abbott Laboratories interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.